Anti ulcer Drug Sales

Ulcer Treatment Market Outlook

The global ulcer treatment market is projected to reach approximately $XX billion by 2035, growing at a CAGR of XX% over the forecast period from 2025 to 2035. The increasing prevalence of gastrointestinal disorders, particularly ulcers, due to lifestyle changes, dietary habits, and rising stress levels is a significant driver for this market's growth. Moreover, advancements in pharmaceutical research and development, leading to the introduction of more effective and targeted therapies, are also expected to contribute to the market's expansion. Factors such as an aging population, which is more susceptible to ulcer-related complications, coupled with the growing awareness of ulcer treatment options, further bolster the market. Additionally, the rising incidence of related conditions such as acid reflux and gastroesophageal reflux disease (GERD) is likely to propel demand for ulcer treatments in the coming years.

Growth Factor of the Market

The ulcer treatment market is primarily driven by the increasing prevalence of ulcers and related gastrointestinal disorders among various demographic groups. With lifestyle changes leading to higher consumption of spicy food, alcohol, and tobacco, the incidence of ulcers has steadily risen, making treatment options more critical than ever. Furthermore, advancements in medical technologies and innovative approaches in drug formulations are enabling manufacturers to provide more effective treatments with fewer side effects. The growing healthcare expenditure in emerging markets is also fostering the development and distribution of ulcer medications, opening up new avenues for growth. Additionally, the rise of e-commerce platforms for medication availability has made it easier for patients to access treatments, thereby driving market growth. Overall, the combination of demographic trends, technological advancements, and increased healthcare accessibility are pivotal factors accelerating the growth of the ulcer treatment market.

Key Highlights of the Market

• Significant growth is expected in the ulcer treatment market due to rising prevalence rates of gastrointestinal disorders.
• Proton Pump Inhibitors (PPIs) are anticipated to dominate the product type segment, given their effectiveness in treating various ulcers.
• Online pharmacies are becoming a preferred distribution channel, offering convenience and accessibility to patients.
• North America is projected to hold the largest market share, driven by advanced healthcare infrastructure and high healthcare expenditure.
• Emerging markets in Asia Pacific are expected to witness substantial growth opportunities due to increasing awareness and improvements in healthcare systems.

By Product Type

Proton Pump Inhibitors:

Proton Pump Inhibitors (PPIs) represent a significant segment in the ulcer treatment market, primarily due to their effectiveness in reducing gastric acid production. Medications such as omeprazole and pantoprazole are widely used to treat various types of ulcers and gastroesophageal reflux disease (GERD). The high demand for PPIs can be attributed to their ability to provide rapid relief from ulcer-related symptoms and promote healing. Additionally, the convenience of once-daily dosing enhances patient compliance, making PPIs a preferred choice among healthcare practitioners. As research continues to unveil the long-term benefits and safety profiles of these drugs, the market for PPIs is expected to expand further, particularly in developed regions.

H2 Receptor Antagonists:

H2 Receptor Antagonists, such as ranitidine and famotidine, play a crucial role in the ulcer treatment market, particularly for patients seeking alternatives to PPIs. These medications function by blocking histamine receptors in the stomach lining, thereby reducing acid secretion and providing symptomatic relief from ulcer-related discomfort. While their market share has been affected by the emergence of PPIs, H2 antagonists still hold substantial demand due to their efficacy and affordability. Moreover, they are often recommended for patients who experience less severe symptoms or require long-term management of gastric acid secretion. The ongoing research on the safety and effectiveness of these medications is likely to sustain their relevance in the ulcer treatment landscape.

Antacids:

Antacids are widely used in the ulcer treatment market for their immediate relief of heartburn and acid indigestion symptoms. These over-the-counter medications, which include compounds like magnesium hydroxide and calcium carbonate, neutralize stomach acid and provide quick comfort. Their ease of accessibility and low cost contribute to their popularity among patients, especially those with mild ulcer symptoms. The antacid segment's market is characterized by a growing preference for chewable tablets and liquid formulations, catering to different patient preferences. As awareness about gastrointestinal health increases, antacids are likely to remain a staple in the management of ulcer-related discomfort, although they may not be sufficient as standalone treatments for more severe cases.

Antibiotics:

Antibiotics are essential in the ulcer treatment market, particularly for treating peptic ulcers caused by Helicobacter pylori infection. These medications, including amoxicillin and clarithromycin, are often administered in combination with PPIs to eradicate the bacteria and promote ulcer healing. The increasing awareness regarding the link between H. pylori and ulcer formation has led to a surge in the use of antibiotic therapies. The segment is also supported by ongoing research into the efficacy of various antibiotic combinations in enhancing treatment outcomes. As global health organizations emphasize the importance of H. pylori eradication, the demand for effective antibiotic regimens in ulcer therapy is expected to rise significantly.

Prostaglandin Analogues:

Prostaglandin Analogues, such as misoprostol, are utilized in ulcer treatment primarily to protect the stomach lining and prevent the formation of ulcers, especially in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). These medications work by increasing gastric mucus and bicarbonate secretion, promoting mucosal blood flow, and thereby enhancing the stomach's defense mechanisms against acid. The adoption of prostaglandin analogues is crucial in specific patient populations, particularly those at high risk for NSAID-induced ulcers. Despite their relatively smaller market share compared to PPIs and antibiotics, their role in ulcer prevention and management cannot be overlooked. As awareness of the risks associated with long-term NSAID use increases, the market for prostaglandin analogues is likely to gain traction.

By Application

Gastric Ulcers:

Gastric ulcers, which occur on the lining of the stomach, account for a significant portion of the ulcer treatment market. These ulcers can be caused by a variety of factors, including H. pylori infection, excessive use of NSAIDs, and stress. The treatment for gastric ulcers typically involves the use of PPIs to reduce acid secretion and promote healing of the gastric mucosa. The rising incidence of gastric ulcers, driven by lifestyle changes and dietary habits, is expected to fuel the demand for effective treatment options. Ongoing research into the pathophysiology of gastric ulcers is also paving the way for innovative therapies, further supporting market growth in this application segment.

Duodenal Ulcers:

Duodenal ulcers, which develop in the upper part of the small intestine, are another significant segment of the ulcer treatment market. These ulcers are often associated with H. pylori infection and are characterized by intermittent abdominal pain. Effective management typically requires a combination of PPIs and antibiotics to address both acid production and bacterial eradication. The increasing prevalence of duodenal ulcers, particularly in younger populations, is likely to drive demand for targeted treatment therapies in this segment. As awareness regarding gastrointestinal health improves, healthcare providers are focusing on early diagnosis and effective management of duodenal ulcers, further bolstering market growth.

Peptic Ulcers:

Peptic ulcers encompass both gastric and duodenal ulcers, representing a broader application segment in the ulcer treatment market. The rising prevalence of peptic ulcers due to factors such as poor dietary habits and stress is contributing to an increased demand for effective treatment options. The treatment approach usually involves a combination of PPIs, antibiotics, and sometimes H2 receptor antagonists, tailored to the specific needs of individual patients. The growing recognition of the importance of addressing the underlying causes of peptic ulcers has led to an increase in preventive measures and lifestyle modifications, thus supporting the growth of this application segment in the market.

By Distribution Channel

Hospitals:

Hospitals play a critical role in the distribution of ulcer treatment medications, particularly for patients requiring hospitalization due to severe ulcer complications. The hospital setting often provides access to specialized care and a broader range of treatment options, including intravenous medications for urgent cases. The increasing number of hospital admissions related to gastrointestinal disorders is driving demand for ulcer treatments in this channel. Additionally, hospitals are crucial for educating patients about their conditions and available treatment options, which can lead to improved patient adherence post-discharge. The trend towards more integrated healthcare systems is likely to enhance the role of hospitals in ulcer treatment distribution further.

Retail Pharmacies:

Retail pharmacies are a vital distribution channel for ulcer treatment medications, offering convenience and accessibility to patients seeking over-the-counter solutions. This channel allows patients to obtain medications such as antacids and H2 receptor antagonists without a prescription, catering to those with mild symptoms. Retail pharmacies often engage in patient education and counseling, providing valuable information about ulcer management and appropriate use of medications. The growth of retail pharmacy chains, coupled with increased consumer awareness of gastrointestinal health, is expected to fuel the demand for ulcer treatments in this channel. Furthermore, the competitive pricing and promotions offered by retail pharmacies contribute to their popularity among consumers.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for ulcer treatment medications, particularly in the wake of the COVID-19 pandemic, which accelerated the adoption of e-commerce in healthcare. The convenience of ordering medications from home, combined with home delivery options, has become increasingly appealing to consumers. Online pharmacies not only provide a wide range of ulcer treatment options but also often offer competitive pricing and discounts. Additionally, they facilitate access to medications for individuals in remote areas with limited healthcare facilities. As consumers continue to embrace the convenience of online shopping, the role of online pharmacies in the ulcer treatment market is expected to grow robustly in the coming years.

By Ingredient Type

Omeprazole:

Omeprazole is one of the most widely prescribed medications in the ulcer treatment market, primarily due to its effectiveness as a proton pump inhibitor. It works by inhibiting gastric acid secretion, providing relief from ulcer-related symptoms and promoting healing. The widespread use of omeprazole is attributed to its favorable safety profile and ease of administration. As research continues to highlight its efficacy in treating various ulcer types, particularly in combination therapies, the demand for omeprazole is expected to remain strong. Furthermore, the availability of generic formulations has made omeprazole more accessible to patients, further driving its market growth.

Ranitidine:

Ranitidine, an H2 receptor antagonist, has traditionally played a crucial role in the ulcer treatment market by reducing stomach acid production. Although recent controversies regarding its safety have impacted its market presence, it remains an important option for patients who prefer alternatives to PPIs. Ranitidine's role in treating gastric and duodenal ulcers has been well-established, and its affordability makes it an attractive choice for many consumers. The ongoing development of safer H2 antagonists and the focus on patient education regarding proper usage are expected to shape the future demand for ranitidine in the ulcer treatment market.

Pantoprazole:

Pantoprazole is another key ingredient in the ulcer treatment market, recognized for its efficacy as a proton pump inhibitor. It is particularly favored for its rapid action and longer duration of effect, making it suitable for various ulcer indications, including peptic ulcers and GERD. As healthcare providers increasingly recognize the benefits of pantoprazole in managing acid-related disorders, its demand is expected to grow. Additionally, the introduction of different formulations, such as injectable options, expands its usability in hospital settings, further enhancing its market presence.

Amoxicillin:

Amoxicillin is a crucial antibiotic in the ulcer treatment market, particularly for its role in eradicating H. pylori infections, which are linked to peptic ulcer formation. The combination of amoxicillin with PPIs has become a standard treatment regimen for patients diagnosed with H. pylori-associated ulcers. The effectiveness of amoxicillin, combined with its favorable safety profile, makes it a preferred choice among healthcare practitioners. With ongoing studies validating its use in various antibiotic regimens, the demand for amoxicillin in ulcer treatment is expected to sustain its growth in the market.

Misoprostol:

Misoprostol, a prostaglandin analogue, is primarily used in preventing NSAID-induced ulcers by enhancing gastric mucosa protection. Although its market share is small compared to PPIs and antibiotics, misoprostol remains essential for specific patient populations at risk for ulcer formation. The increased awareness regarding the risks associated with prolonged NSAID use is likely to boost the demand for misoprostol in the ulcer treatment market. As new research highlights the benefits of misoprostol in combination with other ulcer medications, its role is expected to become increasingly significant.

By Region

The North American region is anticipated to hold the largest market share for ulcer treatments, driven by advanced healthcare infrastructure, high healthcare spending, and a well-established pharmaceutical industry. The increasing prevalence of gastrointestinal disorders, coupled with a robust regulatory framework that supports drug approval processes, positions North America at the forefront of the ulcer treatment market. According to recent estimates, this region accounts for nearly XX% of the global market share, reflecting the growing demand for effective ulcer therapies among consumers. The focus on research and development of innovative treatment options further strengthens North America's leadership in this market segment.

Europe is also experiencing substantial growth in the ulcer treatment market, with a projected CAGR of XX% over the forecast period. Factors such as the increasing prevalence of gastric and duodenal ulcers, heightened awareness of gastrointestinal health, and advancements in treatment options are driving this growth. The presence of key pharmaceutical manufacturers and research institutions in countries such as Germany, France, and the UK further supports the development and availability of ulcer medications. Additionally, the region's comprehensive healthcare systems ensure that patients have access to a wide range of treatment options, contributing to the overall market expansion.

Opportunities

The ulcer treatment market presents numerous opportunities, particularly in emerging economies where healthcare systems are rapidly evolving. As disposable incomes rise and healthcare access improves, there is an increasing demand for effective ulcer treatments. Pharmaceutical companies can capitalize on this growing market by investing in research and development to create innovative therapies tailored to the unique needs of these populations. Additionally, the introduction of educational programs focused on gastrointestinal health can help raise awareness about ulcer prevention and treatment, further expanding market opportunities. Collaborations with healthcare providers and local governments can facilitate the introduction of effective ulcer treatments in these regions, driving growth and improving patient outcomes.

Moreover, the growing trend towards personalized medicine in the healthcare sector offers significant potential for the ulcer treatment market. By leveraging genetic and molecular insights, pharmaceutical companies can develop targeted therapies that address the specific needs of individual patients, improving treatment efficacy and safety. This shift towards personalized approaches is already being observed in other therapeutic areas and is likely to gain traction in ulcer treatment as well. The integration of technology, such as telemedicine and mobile health applications, can also enhance patient engagement and adherence to treatment regimens, ultimately leading to better health outcomes and market growth.

Threats

Despite the promising growth prospects, the ulcer treatment market faces several threats that could hinder its progress. One major concern is the increasing prevalence of antibiotic resistance, which poses a significant challenge in treating H. pylori infections, a primary cause of peptic ulcers. As bacteria develop resistance to commonly prescribed antibiotics, healthcare providers face difficulties in selecting effective treatment regimens, which could lead to higher healthcare costs and less favorable patient outcomes. Furthermore, regulatory challenges and stringent approval processes for new medications can slow down the introduction of innovative ulcer treatments into the market, limiting options for patients and providers alike.

Additionally, the rise of alternative therapies and natural remedies for gastrointestinal disorders could pose a threat to traditional pharmaceutical treatments. As consumers become more health-conscious and interested in holistic approaches to medicine, there is a growing trend towards the use of dietary supplements and herbal remedies for ulcer management. This shift in consumer preferences may lead to decreased demand for conventional ulcer medications, impacting the market share of established pharmaceutical companies. To remain competitive, the industry must adapt to these changing consumer attitudes by integrating complementary therapies into traditional treatment regimens while continuing to emphasize the importance of evidence-based medicine.

Competitor Outlook

• Pfizer Inc.
• GlaxoSmithKline Plc
• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• Novartis AG
• Johnson & Johnson
• Merck & Co., Inc.
• AbbVie Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals Plc
• Endo International Plc

The competitive landscape of the ulcer treatment market is characterized by a robust mix of well-established pharmaceutical companies and emerging players. Major companies such as Pfizer and GlaxoSmithKline dominate the market, offering a wide range of ulcer medications, including PPIs and antibiotics. The presence of strong research and development capabilities allows these companies to continuously innovate and introduce new treatment options to meet evolving patient needs. Furthermore, their extensive distribution networks ensure that ulcer treatments are widely available across different healthcare settings, enhancing patient access and compliance.

Emerging companies are also making their mark on the ulcer treatment market by focusing on niche segments and developing specialized products. For instance, companies like Takeda and AstraZeneca are investing in research to identify new therapeutic targets and develop innovative formulations that address specific ulcer-related conditions. This trend towards specialization is likely to intensify competition as companies seek to differentiate themselves through product offerings and marketing strategies. Additionally, partnerships and collaborations among pharmaceutical companies, healthcare providers, and research institutions are becoming increasingly common, enabling more effective drug development and distribution strategies.

Key players such as Johnson & Johnson and Merck are actively involved in expanding their portfolios through acquisitions and collaborations, further enhancing their market positions. For example, Merck's acquisition of various biotech companies has strengthened its capabilities in developing novel ulcer treatments, while Johnson & Johnson's focus on combination therapies aims to improve treatment outcomes for patients with complex gastrointestinal conditions. By leveraging their strengths in research and development, marketing, and distribution, these major companies are well-positioned to capitalize on the growth opportunities within the ulcer treatment market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca Plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline Plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Endo International Plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim GmbH
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals Plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sun Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Anti ulcer Drug Sales Market, By Application
    • 6.1.1 Gastric Ulcers
    • 6.1.2 Duodenal Ulcers
    • 6.1.3 Peptic Ulcers
  • 6.2 Anti ulcer Drug Sales Market, By Product Type
    • 6.2.1 Proton Pump Inhibitors
    • 6.2.2 H2 Receptor Antagonists
    • 6.2.3 Antacids
    • 6.2.4 Antibiotics
    • 6.2.5 Prostaglandin Analogues
  • 6.3 Anti ulcer Drug Sales Market, By Ingredient Type
    • 6.3.1 Omeprazole
    • 6.3.2 Ranitidine
    • 6.3.3 Pantoprazole
    • 6.3.4 Amoxicillin
    • 6.3.5 Misoprostol
  • 6.4 Anti ulcer Drug Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Anti ulcer Drug Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Anti ulcer Drug Sales market is categorized based on

By Product Type

• Proton Pump Inhibitors
• H2 Receptor Antagonists
• Antacids
• Antibiotics
• Prostaglandin Analogues

By Application

• Gastric Ulcers
• Duodenal Ulcers
• Peptic Ulcers

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Omeprazole
• Ranitidine
• Pantoprazole
• Amoxicillin
• Misoprostol

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• GlaxoSmithKline Plc
• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• Novartis AG
• Johnson & Johnson
• Merck & Co., Inc.
• AbbVie Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals Plc
• Endo International Plc